Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Related Posts

Artificial intelligence-derived splenic response in cardiac positron emission tomography is associated with major adverse cardiovascular events: a multi-site study

Ramirez G, Dharmavaram NL, Shanbhag A, Miller RJH, Kavanagh PB, Yi J, Lemley M, Builoff V, Marcinkiewicz A, Dey D, Hainer J, Wopperer S, Knight[...]

Deep learning-enabled screening of chronic kidney disease from echocardiography

Yuan V, Ieki H, Sandhu A, Nguyen LH, Cheng PP, Chang ST, Ambrosy AP, Kwan AC, Go AS, Cheng S, Ouyang D. Deep learning-enabled screening[...]

Specific targeting of cancer cell mitochondria with a malaria drug improves pancreatic cancer outcome

Ou Y, Lim A, Wang R, Mir N, Calsavara VF, Wang Q, Zhang Y, Pandol SJ, Edderkaoui M. Specific targeting of cancer cell mitochondria with[...]